NASDAQ:EPZM - Epizyme Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.00
  • Forecasted Upside: 109.88 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.10
▼ -0.13 (-1.58%)
1 month | 3 months | 12 months
Get New Epizyme Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EPZM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EPZM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.00
▲ +109.88% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Epizyme in the last 3 months. The average price target is $17.00, with a high forecast of $27.00 and a low forecast of $13.00. The average price target represents a 109.88% upside from the last price of $8.10.
Hold
The current consensus among 7 contributing investment analysts is to hold stock in Epizyme. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$13.00High
i
3/3/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$14.00N/A
i
2/25/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$14.00High
i
2/24/2021CitigroupLower Price Target$35.00 ➝ $27.00Medium
i
2/23/2021WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
2/5/2021SVB LeerinkReiterated RatingMarket PerformLow
i
Rating by A. Berens at SVB Leerink LLC
12/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $14.00Low
i
11/9/2020Morgan StanleyLower Price TargetOverweight$29.00 ➝ $27.00High
i
11/9/2020BarclaysLower Price TargetOverweight$33.00 ➝ $18.00High
i
8/5/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $29.00Medium
i
6/19/2020SVB LeerinkLower Price TargetMarket Perform$18.00 ➝ $16.00High
i
Rating by Andrew Berens at SVB Leerink LLC
6/19/2020Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $31.00High
i
5/5/2020OppenheimerReiterated RatingHold$16.00 ➝ $17.00High
i
4/1/2020OppenheimerDowngradeOutperform ➝ Market Perform$17.00 ➝ $16.00High
i
3/4/2020BarclaysInitiated CoverageOverweight$33.00High
i
2/25/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $36.00Low
i
Rating by A. Fein at HC Wainwright
1/24/2020Morgan StanleyBoost Price TargetOverweight$26.00 ➝ $28.00High
i
Rating by David Lebovitz at Morgan Stanley
1/24/2020CowenBoost Price TargetOutperform$18.00 ➝ $36.00High
i
1/24/2020WedbushBoost Price TargetOutperform$24.00 ➝ $30.00High
i
1/23/2020CitigroupBoost Price TargetBuy$25.00 ➝ $35.00Medium
i
12/19/2019WedbushReiterated RatingOutperform$24.00High
i
12/5/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $22.00High
i
10/31/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by A. Fein at HC Wainwright
10/31/2019CowenReiterated RatingBuy$18.00Low
i
6/24/2019HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Andrew Fein at HC Wainwright
6/13/2019HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Andrew Fein at HC Wainwright
6/12/2019WedbushReiterated RatingOutperform$21.00Low
i
5/31/2019HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Andrew Fein at HC Wainwright
5/30/2019CitigroupReiterated RatingBuyHigh
i
2/27/2019Roth CapitalReiterated RatingBuyLow
i
Rating by J. Marango at Roth Capital
2/27/2019OppenheimerLower Price TargetOutperform$27.00 ➝ $18.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
2/26/2019CowenReiterated RatingBuy$18.00Medium
i
1/7/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00High
i
Rating by A. Berens at SVB Leerink LLC
1/4/2019OppenheimerSet Price TargetBuy$27.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
11/15/2018OppenheimerSet Price TargetBuy$27.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/5/2018Morgan StanleyLower Price TargetEqual Weight ➝ Hold$12.00 ➝ $11.00Low
i
Rating by David Lebovitz at Morgan Stanley
11/5/2018WedbushReiterated RatingOutperform$21.00Medium
i
11/2/2018OppenheimerSet Price TargetBuy$27.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/22/2018Roth CapitalSet Price TargetBuy$26.00 ➝ $18.00Low
i
Rating by Jotin Marango at Roth Capital
9/25/2018SunTrust BanksBoost Price TargetBuy$25.00Medium
i
9/24/2018SVB LeerinkInitiated CoverageMarket Perform$11.00Medium
i
Rating by G. Porges at SVB Leerink LLC
9/24/2018CowenReiterated RatingBuyHigh
i
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightLow
i
Rating by David Lebovitz at Morgan Stanley
9/7/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$12.00Medium
i
7/3/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00High
i
Rating by Geoff Porges at SVB Leerink LLC
6/27/2018HC WainwrightReiterated RatingBuy$25.00High
i
5/21/2018HC WainwrightReiterated RatingBuy$25.00Low
i
5/18/2018WedbushBoost Price Target$20.00 ➝ $25.00Low
i
Rating by D. Nierengarten at Wedbush
4/24/2018Roth CapitalSet Price TargetBuy$24.00Medium
i
Rating by Jotin Marango at Roth Capital
4/24/2018SVB LeerinkSet Price TargetBuy$24.00High
i
Rating by Geoff Porges at SVB Leerink LLC
4/24/2018WedbushLower Price TargetHold ➝ Outperform$24.00 ➝ $20.00High
i
Rating by D. Nierengarten at Wedbush
4/24/2018SunTrust BanksLower Price TargetBuy ➝ Hold$20.00High
i
3/14/2018WedbushReiterated RatingOutperform$26.00 ➝ $25.00High
i
Rating by D. Nierengarten at Wedbush
3/14/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$22.00 ➝ $24.00High
i
3/14/2018SunTrust BanksReiterated RatingBuy$27.00High
i
2/1/2018Roth CapitalInitiated CoverageBuy$24.00Medium
i
Rating by J. Marango at Roth Capital
1/24/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$25.00Low
i
1/10/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00High
i
12/12/2017OppenheimerSet Price TargetBuy$26.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/2/2017HC WainwrightReiterated RatingBuy$25.00N/A
i
Rating by J. Marango at HC Wainwright
11/2/2017SVB LeerinkReiterated RatingOutperform$28.00 ➝ $22.00N/A
i
11/2/2017Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$20.00 ➝ $16.00N/A
i
Rating by Matthew Eckler at Royal Bank of Canada
9/20/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$23.00Medium
i
9/19/2017OppenheimerReiterated RatingBuy$26.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
9/15/2017Royal Bank of CanadaReiterated RatingBuy$20.00Low
i
Rating by Matthew Eckler at Royal Bank of Canada
8/9/2017SVB LeerinkReiterated RatingOutperform$31.00 ➝ $28.00Medium
i
8/7/2017HC WainwrightReiterated RatingBuyMedium
i
Rating by J. Marango at HC Wainwright
8/5/2017Royal Bank of CanadaSet Price TargetBuy$20.00High
i
Rating by Matthew Eckler at Royal Bank of Canada
6/16/2017SVB LeerinkReiterated RatingOutperform$31.00High
i
6/16/2017CitigroupBoost Price TargetBuy$20.00 ➝ $22.00Low
i
6/14/2017OppenheimerSet Price TargetBuy$26.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
6/12/2017Royal Bank of CanadaSet Price TargetBuy$20.00Low
i
Rating by Matthew Eckler at Royal Bank of Canada
6/7/2017CowenReiterated RatingBuyHigh
i
6/7/2017HC WainwrightReiterated RatingBuy$25.00Medium
i
6/5/2017OppenheimerSet Price TargetBuy$26.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
5/19/2017HC WainwrightReiterated RatingBuyLow
i
5/18/2017WedbushReiterated RatingOutperform$24.00High
i
5/10/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00 ➝ $20.00Low
i
4/13/2017CIBCReiterated RatingOutperform ➝ OutperformLow
i
4/13/2017OppenheimerInitiated CoverageOutperform$26.00Low
i
3/11/2017Royal Bank of CanadaReiterated RatingOutperform$26.00 ➝ $19.00N/A
i
11/28/2016WedbushReiterated RatingOutperform$22.00N/A
i
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Michael King at JMP Securities
11/6/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
11/4/2016WedbushReiterated RatingOutperform$22.00N/A
i
10/7/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by G. Porges at SVB Leerink LLC
8/9/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
6/23/2016JMP SecuritiesReiterated RatingBuy$28.00N/A
i
6/21/2016SVB LeerinkReiterated RatingOutperform$39.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
6/20/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
6/20/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
6/20/2016MizuhoReiterated RatingBuy$18.00N/A
i
Rating by Eric Criscuolo at Mizuho
6/20/2016Royal Bank of CanadaReiterated RatingOutperform$26.00N/A
i
5/10/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
5/10/2016MizuhoLower Price TargetBuy$20.00 ➝ $18.00N/A
i
Rating by Eric Criscuolo at Mizuho
5/9/2016WedbushReiterated RatingOutperform$22.00N/A
i
4/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
(Data available from 4/18/2016 forward)
Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.10
$7.85
$8.33

50 Day Range

MA: $8.80
$7.45
$9.78

52 Week Range

Now: $8.10
$7.44
$22.00

Volume

1,164,756 shs

Average Volume

1,097,448 shs

Market Capitalization

$824.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Epizyme?

The following Wall Street research analysts have issued reports on Epizyme in the last year: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for EPZM.

What is the current price target for Epizyme?

7 Wall Street analysts have set twelve-month price targets for Epizyme in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 109.9%. Citigroup Inc. has the highest price target set, predicting EPZM will reach $27.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $13.00 for Epizyme in the next year.
View the latest price targets for EPZM.

What is the current consensus analyst rating for Epizyme?

Epizyme currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EPZM, but not buy more shares or sell existing shares.
View the latest ratings for EPZM.

What other companies compete with Epizyme?

How do I contact Epizyme's investor relations team?

Epizyme's physical mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is 617-229-5872 and its investor relations email address is [email protected] The official website for Epizyme is www.epizyme.com.